利用放疗前窗口识别成人新诊断胶质母细胞瘤中潜在活性的细胞毒性药物
该综述检索1980至2023年PubMed上关于成人新诊断系统性癌症与脑肿瘤接受放疗前化疗的前瞻性试验,并用美国国家综合癌症网络指南记录其标准使用情况。而在高级别胶质瘤中仅识别出50项类似试验(2206例患者)。含替莫唑胺放疗前化疗的13项试验(n=846)影像学缓解率为6%至53%,中位生存期约13个月;胶质母细胞瘤放疗前化疗试验未伴随意外毒性或对生存的重大负面影响,作者认为其安全可行,放疗前窗口适合快速筛选细胞毒性药物。
要点
- 高级别胶质瘤中仅50项类似试验(2206例患者),远少于实体瘤。
- 含替莫唑胺放疗前化疗的13项试验(n=846)影像学缓解率6%至53%,中位生存期约13个月。
核心结论
- 胶质母细胞瘤患者放疗前化疗似乎安全可行。
- 放疗前窗口非常适合快速筛选细胞毒性药物的疗效。
- 放疗前化疗可能最适合那些不太可能从替莫唑胺获益的胶质母细胞瘤患者。
研究设计与样本
- 本综述检索PubMed上1980年至2023年发表的成人新诊断系统性癌症与脑肿瘤接受放疗前化疗的前瞻性试验。
- 使用美国国家综合癌症网络指南记录放疗前化疗在系统性癌症与脑肿瘤患者中的标准使用情况。
- 在高级别胶质瘤中识别出50项类似试验,共2206例患者。
- 含替莫唑胺放疗前化疗的13项试验共846例患者。
主要发现
- 含替莫唑胺放疗前化疗的13项试验(n=846)中,影像学缓解率范围为6%至53%,中位生存期约13个月。
- 胶质母细胞瘤放疗前化疗试验未伴随意外毒性或对生存的重大负面影响。
- 放疗前窗口允许以影像学缓解作为主要结局、采用小样本量,并在诊断后几个月内启动标准治疗。
关键数值与推荐
- 高级别胶质瘤中放疗前化疗试验为50项,共2206例患者。
- 含替莫唑胺放疗前化疗的13项试验(n=846)影像学缓解率为6%至53%,中位生存期约13个月。
临床怎么用
- 作者认为放疗前化疗在胶质母细胞瘤患者中似乎安全可行。
- 作者认为放疗前窗口非常适合快速筛选细胞毒性药物的疗效。
- 作者认为放疗前化疗可能最适合那些不太可能从替莫唑胺获益的胶质母细胞瘤患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Therapies shown to improve outcomes in patients with recurrent cancers are commonly used in the neoadjuvant setting to optimize surgery, reduce radiation fields, and treat micrometastatic disease. While the use of pre-radiation chemotherapy (PRC) has flourished in systemic cancers, it has not seen the same level of use in glioblastomas. This review documents these trajectories and highlights the potential of PRC to rapidly and safely screen cytotoxic drugs for efficacy in patients with newly diagnosed glioblastoma. Prospective trials of adults with newly diagnosed systemic and brain cancers treated with PRC published between 1980 and 2023 were identified in PubMed. The National Comprehensive Cancer Network guidelines were used to document the standard use of PRC in patients with systemic and brain cancers. Over 5000 prospective PRC trials in solid tumors were identified. These accrued >1 million patients and resulted in neoadjuvant therapies being the standard of care in ~28 systemic cancers. Only 50 similar trials (2206 patients) were identified in high-grade gliomas. In 13 trials containing PRC temozolomide (n = 846), radiographic responses ranged from 6 to 53% with a median survival of ~13 months. Glioblastoma PRC trials were not associated with unexpected toxicities or major negative impacts on survival. Pre-radiation chemotherapy in patients with glioblastoma appears safe and feasible. The pre-radiation window is ideally suited to rapidly screen cytotoxic agents for efficacy. It permits radiographic response as a primary outcome, small sample sizes, and initiation of standard therapies a few months after diagnosis. Pre-radiation chemotherapy may be most appropriate for patients with glioblastoma who are unlikely to benefit from temozolomide.
引用
- Bazer DA, Wolff AC, Grossman SA, et al. Using a pre-radiation window to identify potentially active cytotoxic agents in adults with newly diagnosed glioblastoma. Neuro Oncol. 2025. PMID: 39535058. doi:10.1093/neuonc/noae240
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。